Individualized dosing regimen for prothrombin complex concentrate more effective than standard treatment in the reversal of oral anticoagulant therapy: An open, prospective randomized controlled trial

Thrombosis Research

Volumn 118, Issue 3, 2006, Pages 313-320

  van Aart, Lonneke ^a   Eijkhout, Heleen W ^b   Kamphuis, Jan S ^a   Dam, Marco ^a   Schattenkerk, Marinus Eeftinck ^a   Schouten, Teunis J ^b   Ploeger, Ben ^a   Strengers, Paul F W ^b  

^a DEVENTER HOSPITAL   (Netherlands)

^b Medical Department   (Netherlands)

Author keywords

Acute reversal of anticoagulant drugs; Coagulation factors; Cofact ; Haemostasis; PCC; Prothrombin complex concentrates

Indexed keywords

ANTICOAGULANT AGENT; ARTICAINE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; BUPIVACAINE; COFACT; PROTHROMBIN; PROTHROMBIN COMPLEX; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BLEEDING; BODY WEIGHT; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; EEG ABNORMALITY; EVALUATION; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPOTENSION; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SOMNOLENCE; SPEECH DISORDER; THERAPY EFFECT; THROMBOEMBOLISM; TREATMENT RESPONSE;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; BLOOD COAGULATION FACTORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEMORRHAGE; HUMANS; MALE; THROMBOSIS; TREATMENT OUTCOME;

EID: 33746787177     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2005.08.005     Document Type: Article

References (31)

1. Makris M., and Watson H.G. The management of coumarin-induced over-anticoagulation annotation. Br J Haematol 114 2 (2001) 271-280
2. van der Meer F.J., Rosendaal F.R., Vandenbroucke J.P., and Briet E. Bleeding complications in oral anticoagulant therapy. An analysis of risk factors. Arch Intern Med 153 13 (1993) 1557-1562
3. Ansell J., Hirsh J., Poller L., Bussey H., Jacobson A., and Hylek E. The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126 3 Suppl (2004) 204S-233S
4. Palareti G., Leali N., Coccheri S., Poggi M., Manotti C., D'Angelo A., et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet 348 9025 (1996) 423-428
5. Fihn S.D., McDonell M., Martin D., Henikoff J., Vermes D., Kent D., et al. Risk factors for complications of chronic anticoagulation. A multicenter study. Warfarin optimized outpatient follow-up study group. Ann Intern Med 118 7 (1993) 511-520
6. Schenk J.F., Morsdorf S., Pindur G., Munter K.H., Thrun F., Tiaden J.D., et al. Analysis and occurrence of adverse events with oral anticoagulant therapy. Semin Thromb Hemost 25 1 (1999) 65-71
7. White R.H., McKittrick T., Takakuwa J., Callahan C., McDonell M., and Fihn S. Management and prognosis of life-threatening bleeding during warfarin therapy. National Consortium of Anticoagulation Clinics. Arch Intern Med 156 11 (1996) 1197-1201
8. British Committee for Standards in Haematology. Guidelines on oral anticoagulation: third edition. Br J Haematol 101 2 (1998) 374-387
9. Ansell J., Hirsh J., Dalen J., Bussey H., Anderson D., Poller L., et al. Managing oral anticoagulant therapy. Chest 119 1 Suppl (2001) 22S-38S
10. Halbmayer W.M. Rational, high quality laboratory monitoring before, during, and after infusion of prothrombin complex concentrates. Thromb Res 95 4 Suppl 1 (1999) S25-S30
11. Boulis N.M., Bobek M.P., Schmaier A., and Hoff J.T. Use of factor IX complex in warfarin-related intracranial hemorrhage. Neurosurgery 45 5 (1999) 1113-1118
12. Butler A.C., and Tait R.C. Management of oral anticoagulant-induced intracranial haemorrhage. Blood Rev 12 1 (1998) 35-44
13. Makris M., Greaves M., Phillips W.S., Kitchen S., Rosendaal F.R., and Preston E.F. Emergency oral anticoagulant reversal: the relative efficacy of infusions of fresh frozen plasma and clotting factor concentrate on correction of the coagulopathy. Thromb Haemost 77 3 (1997) 477-480
14. Nitu I.C., Perry D.J., and Lee C.A. Clinical experience with the use of clotting factor concentrates in oral anticoagulation reversal. Clin Lab Haematol 20 6 (1998) 363-367
15. Fredriksson K., Norrving B., and Stromblad L.G. Emergency reversal of anticoagulation after intracerebral hemorrhage. Stroke 23 7 (1992) 972-977
16. Cartmill M., Dolan G., Byrne J.L., and Byrne P.O. Prothrombin complex concentrate for oral anticoagulant reversal in neurosurgical emergencies. Br J Neurosurg 14 5 (2000) 458-461
17. Preston F.E., Laidlaw S.T., Sampson B., and Kitchen S. Rapid reversal of oral anticoagulation with warfarin by a prothrombin complex concentrate (Beriplex): efficacy and safety in 42 patients. Br J Haematol 116 3 (2002) 619-624
18. Over, J. Cofact, a double virus inactivated prothrombin complex concentrate. Downstream 31, 26. 2003. Amersham Pharmacia Biotech UK Ltd 2000. 1-1-2003. Ref Type: Electronic Citation
19. ICSH/ICTH. ICSH/ICTH recommendations for reporting prothrombin time in oral anticoagulant control. International Committee for Standardization in Haematology and International Committee on Thrombosis and Haemostasis. J Clin Pathol 38 2 (1985) 133-134
20. Editorial. Oral anticoagulant control. Lancet 2 8557 (1987) 488-489
21. Morfini M., Longo G., Berntorp E., Cinotti S., Filimberti E., Messori A., et al. Pharmacokinetics, thrombogenicity and safety of a double-treated prothrombin complex concentrate. Thromb Res 71 3 (1993) 175-184
22. German Medical Association. Guidelines for therapy with blood components and plasma derivatives. 2 ed. (2001), Council and Scientific Advisory Board of the German Medical Association, Cologne
23. Lubetsky A., Shasha Y., Olchovsky D., Loebstein R., Halkin H., and Ezra D. Impact of pre-treatment INR level on the effect of intravenous low dose vitamin K in patients with excessive anticoagulation. Thromb Haemost 90 1 (2003) 71-76
24. Gunther K.E., Conway G., Leibach L., and Crowther M.A. Low-dose oral vitamin K is safe and effective for outpatient management of patients with an INR > 10. Thromb Res 113 3-4 (2004) 205-209
25. Fihn S.D., Callahan C.M., Martin D.C., McDonell M.B., Henikoff J.G., and White R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 124 11 (1996) 970-979
26. Poon M.C., Aledort L.M., Anderle K., Kunschak M., and Morfini M. Comparison of the recovery and half-life of a high-purity factor IX concentrate with those of a factor IX complex concentrate. Factor IX Study Group. Transfusion 35 4 (1995) 319-323
27. Ménaché D. The turnover rate of the coagulation factors II, VII and IX under normal metabolic conditions. Thromb Diath Haemorrh Suppl 13 (1964) 187-194
28. Lubetsky A., Hoffman R., Zimlichman R., Eldor A., Zvi J., Kostenko V., et al. Efficacy and safety of a prothrombin complex concentrate (Octaplex) for rapid reversal of oral anticoagulation. Thromb Res 113 6 (2004) 371-378
29. Kohler M., Hellstern P., Lechler E., Uberfuhr P., and Muller-Berghaus G. Thromboembolic complications associated with the use of prothrombin complex and factor IX concentrates. Thromb Haemost 80 3 (1998) 399-402
30. Evans G., Luddington R., and Baglin T. Beriplex P/N reverses severe warfarin-induced overanticoagulation immediately and completely in patients presenting with major bleeding. Br J Haematol 115 4 (2001) 998-1001
31. Lind S.E., Callas P.W., Golden E.A., Joyner Jr. K.A., and Ortel T.L. Plasma levels of factors II, VII and X and their relationship to the international normalized ratio during chronic warfarin therapy. Blood Coagul Fibrinolysis 8 1 (1997) 48-53